NASDAQ:ZY Zymergen (ZY) Stock Price, News & Analysis → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Free ZY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.43▼$2.4350-Day Range$2.35▼$3.1452-Week Range$1.10▼$12.42Volume85 shsAverage Volume1.23 million shsMarket Capitalization$253.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zymergen alerts: Email Address Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Zymergen Stock (NASDAQ:ZY)Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.Read More Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW ZY Stock News HeadlinesApril 10, 2024 | finance.yahoo.comMethod Communications Introduces New Leadership Structure to Accelerate MomentumMarch 21, 2024 | tmcnet.comMolecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029April 19, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 13, 2024 | msn.comGM Appoints Former Tesla and Google Executive to Succeed Retiring Head of ManufacturingMarch 13, 2024 | marketwatch.comGM Taps Former Tesla Gigafactory Head To Lead ManufacturingMarch 1, 2024 | finance.yahoo.comQ4 2023 Ginkgo Bioworks Holdings Inc Earnings CallFebruary 13, 2024 | finance.yahoo.comMATTERWORKS ANNOUNCES BOARD UPDATESJanuary 19, 2024 | bizjournals.comSmartLabs gets $48M investment; CEO says 'we’re not done'April 19, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…January 11, 2024 | finance.yahoo.comSmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEONovember 8, 2023 | finance.yahoo.comGinkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial ResultsNovember 8, 2023 | msn.comTech and biotech firms slash hundreds of Bay Area jobs as layoffs widenNovember 7, 2023 | msn.comGinkgo Bioworks Holdings Q3 2023 Earnings PreviewOctober 24, 2023 | msn.comGingko Bioworks, Penn State partner on wildlife biothreat researchOctober 4, 2023 | msn.comGinkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcyOctober 4, 2023 | markets.businessinsider.comAnalyst Cautions on Ginkgo Bioworks’ Financial Prospects Despite Promising Collaborations and Sector PositionSeptember 27, 2023 | benzinga.comAccelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A CommitmentsSeptember 19, 2023 | finance.yahoo.comTarsadia Strengthens Venture, Growth & Private Investing Practice with New Sector HeadsSeptember 14, 2023 | sg.news.yahoo.comAl Gore and Lila Preston ask the tough questions in their firm's new climate reportSeptember 13, 2023 | ca.style.yahoo.comAl Gore and Lila Preston question everything in their firm's new climate reportSeptember 13, 2023 | techcrunch.comAl Gore and Lila Preston ask the tough questions in their firm’s new climate reportAugust 22, 2023 | finance.yahoo.comMycoWorks Welcomes Three Executives to Leadership TeamAugust 22, 2023 | venturebeat.comCascade Biocatalysts Secures $2.6 M to Scale Enzymes for BiomanufacturingMay 23, 2023 | bizjournals.comLife sciences incubator in Vacaville looks to attract, retain hub's biotechsMay 17, 2023 | marketwatch.comNano Robots Market Reports, Scope, Methodology, Timelines And Challenges Forecast Till 2030May 16, 2023 | technews.tmcnet.comPrescient Appoints Three New Members to its Board of DirectorsMay 4, 2023 | marketwatch.comNano Robots Market Global Trends, Segmentation and Opportunities Forecast To 2030See More Headlines Receive ZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymergen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:ZY CUSIPN/A CIK1645842 Webwww.zymergen.com Phone415-801-8073FaxN/AEmployees502Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-361,790,000.00 Net Margins-2,508.94% Pretax Margin-2,508.42% Return on Equity-93.37% Return on Assets-61.14% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.47 Sales & Book Value Annual Sales$16.74 million Price / Sales15.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.99 per share Price / Book0.61Miscellaneous Outstanding Shares104,355,000Free Float92,145,000Market Cap$253.58 million OptionableNot Optionable Beta1.69 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Enakshi Singh (Age 44)Chief Financial Officer Comp: $390.3kMr. Dmitriy RyaboyChief Technology OfficerMike DulinDirector of CommunicationsMr. Lincoln GermainChief Commercial OfficerMr. Subodh S. DeshmukhChief Devel. OfficerMr. Devin ScannellSr. VP of Drug DiscoveryMr. Duane Valz J.D.Sec.Ms. Mina Kim (Age 48)Corp. Sec. More ExecutivesKey CompetitorsIntrepid PotashNYSE:IPIPiedmont LithiumNASDAQ:PLLL.B. FosterNASDAQ:FSTRDakota GoldNYSE:DCRayonier Advanced MaterialsNYSE:RYAMView All Competitors ZY Stock Analysis - Frequently Asked Questions What is Joshua Hoffman's approval rating as Zymergen's CEO? 64 employees have rated Zymergen Chief Executive Officer Joshua Hoffman on Glassdoor.com. Joshua Hoffman has an approval rating of 62% among the company's employees. This puts Joshua Hoffman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 58.0% of employees surveyed would recommend working at Zymergen to a friend. When did Zymergen IPO? Zymergen (ZY) raised $401 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 13,600,000 shares at a price of $28.00-$31.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, UBS Investment Bank and Lazard acted as the underwriters for the IPO. This page (NASDAQ:ZY) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymergen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.